WO2001000216A1 - Nouvelle association pharmaceutique a base d'erythromycine et d'un acide dicarboxylique ayant 7 a 13 atomes de carbone - Google Patents
Nouvelle association pharmaceutique a base d'erythromycine et d'un acide dicarboxylique ayant 7 a 13 atomes de carbone Download PDFInfo
- Publication number
- WO2001000216A1 WO2001000216A1 PCT/FR2000/001730 FR0001730W WO0100216A1 WO 2001000216 A1 WO2001000216 A1 WO 2001000216A1 FR 0001730 W FR0001730 W FR 0001730W WO 0100216 A1 WO0100216 A1 WO 0100216A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- erythromycin
- carbon atoms
- dicarboxylic acid
- carboxylic acid
- solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Definitions
- New pharmaceutical combination based on erythromycin and a dicarboxylic acid having 7 to 13 carbon atoms.
- the present invention generally relates to a new pharmaceutical association which finds application in the treatment of acne.
- Erythromycin is an antibiotic agent active on the saprophytic germs of the skin which opposes the bacterial colonization of the pilosebaceous follicle and the inflammatory reaction of acne. Therefore, erythromycin is widely used in the treatment of acne for example in the form of alcoholic solution for local application dosed at 4%.
- erythromycin can, in certain cases, induce bacterial resistance of increasing frequency. It has been discovered, and this constitutes the basis of the present invention, that the combination of erythromycin and a dicarboxylic acid having from 7 to 13 carbon atoms, and in particular azelaic acid, has a pharmacological profile interesting which makes it particularly useful in the treatment of acne. Thus, it has been observed that in this new association the aforementioned dicarboxylic acid avoids the induction of bacterial resistance by optimizing, consequently, the antibiotic action of erythromycin.
- the currently preferred acid is azelaic acid, which can be used either in the form of an acid, or in the form of a salt such as in particular the ammonium salt, or the sodium salt.
- dicarboxylic acids such as, for example, pimelic acid or sebacic acid can also be mentioned in the context of the present invention.
- the pharmaceutical combination in accordance with the present invention will be in a form suitable for local administration by topical route, such as for example in the form of a solution, gel, cream or ointment.
- this composition will be in the form of a solution for local application comprising from 2 to 6% of erythromycin base and from 5 to 20% of dicarboxylic acid having from 7 to 13 carbon atoms.
- composition may advantageously include usual additives making it possible to facilitate the delivery of the active principles in particular at the level of the sebaceous follicle.
- composition can be prepared according to methods known per se, in particular by incorporating the active principle constituted by the aforementioned association with excipients usually used, such as for example 96% ethyl alcohol, in the case of a solution .
- the daily usable dose of erythromycin and dicarboxylic acid having 7 to 13 carbon atoms will, of course, depend on the condition of the patient to be treated.
- the weight ratio of erythromycin to dicarboxylic acid having from 7 to 13 carbon atoms will generally be between approximately 1: 3 and approximately 1: 5 and will preferably be 1: 5.
- a pharmaceutical composition according to the invention will be in the form of an alcoholic solution comprising 4% of erythromycin base and 20% of azelaic acid.
- the present invention also covers a method of therapeutic treatment of acne, characterized in that it consists in applying topically a therapeutically effective amount of a combination of erythromycin and a dicarboxylic acid having 7 to 13 carbon atoms and in particular azelaic acid as defined above.
- a pharmaceutical composition in accordance with the present invention was prepared in the form of an alcoholic solution having the following qualitative and quantitative composition:
- This composition can for example be packaged in a 100 ml bottle. It can be prepared by the following procedure: a) a first solution is prepared comprising erythromycin base, azelaic acid and ethyl alcohol in the proportions mentioned above. b) A second solution is prepared containing propylene glycol and polyethylene glycol 400 in the proportions indicated above. c) The two aforementioned solutions are mixed. d) After filtration, the mixture thus produced can be packaged in the form of a solution.
- the first results obtained using this composition show that, unlike erythromycin alone, the combination in accordance with the present The invention avoids the induction of bacterial resistance and prevents the risk of recurrence of acne.
- composition according to the invention was prepared having the following qualitative and quantitative composition:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00945978A EP1187621A1 (fr) | 1999-06-24 | 2000-06-22 | Nouvelle association pharmaceutique a base d'erythromycine et d'un acide dicarboxylique ayant 7 a 13 atomes de carbone |
AU59892/00A AU5989200A (en) | 1999-06-24 | 2000-06-22 | Novel pharmaceutical combination based on erythromycin and carboxylic acid having 7 to 13 carbon atoms |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9908079A FR2795325A1 (fr) | 1999-06-24 | 1999-06-24 | Nouvelle association pharmaceutique a base d'erythromycine et d'un acide dicarboxylique ayant 7 a 13 atomes de carbone |
FR99/08079 | 1999-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001000216A1 true WO2001000216A1 (fr) | 2001-01-04 |
Family
ID=9547252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2000/001730 WO2001000216A1 (fr) | 1999-06-24 | 2000-06-22 | Nouvelle association pharmaceutique a base d'erythromycine et d'un acide dicarboxylique ayant 7 a 13 atomes de carbone |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1187621A1 (fr) |
AU (1) | AU5989200A (fr) |
FR (1) | FR2795325A1 (fr) |
WO (1) | WO2001000216A1 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0273202A2 (fr) * | 1986-12-23 | 1988-07-06 | Eugene J. Dr. Van Scott | Utilisation d'acides polycarboxyliques améliorant l'activité thérapeutique de compositions topiques contre les infections mycotiques et les taches pigmentées. |
US5756119A (en) * | 1991-10-16 | 1998-05-26 | Richardson-Vicks Inc. | Enhanced skin penetration system for improved topical delivery of drugs |
-
1999
- 1999-06-24 FR FR9908079A patent/FR2795325A1/fr not_active Withdrawn
-
2000
- 2000-06-22 EP EP00945978A patent/EP1187621A1/fr not_active Withdrawn
- 2000-06-22 AU AU59892/00A patent/AU5989200A/en not_active Abandoned
- 2000-06-22 WO PCT/FR2000/001730 patent/WO2001000216A1/fr not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0273202A2 (fr) * | 1986-12-23 | 1988-07-06 | Eugene J. Dr. Van Scott | Utilisation d'acides polycarboxyliques améliorant l'activité thérapeutique de compositions topiques contre les infections mycotiques et les taches pigmentées. |
US5756119A (en) * | 1991-10-16 | 1998-05-26 | Richardson-Vicks Inc. | Enhanced skin penetration system for improved topical delivery of drugs |
Non-Patent Citations (1)
Title |
---|
ROTHE M.J. ET AL: "Acne: Update on therapeutic choices.", CONSULTANT, (APRIL 1999) 39/4 (1061-1080)., XP000901561 * |
Also Published As
Publication number | Publication date |
---|---|
AU5989200A (en) | 2001-01-31 |
FR2795325A1 (fr) | 2000-12-29 |
EP1187621A1 (fr) | 2002-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE891088R (fr) | Composition a base de peroxyde de benzoyle | |
CA1289888C (fr) | Composition therapeutique ou cosmetique sous forme d'une solution liquide deperoxide d'hydrogene essentiellement anhydre | |
JP2006328089A (ja) | 安定な局所レチノイド組成物 | |
CA2133614A1 (fr) | Composition cosmetique ou pharmaceutique pour la peau, anhydre et stable, a base de retinol et son utilisation en vue du traitement des maladies de la peau | |
JP2007520551A (ja) | 皮膚炎症反応治療用組成とその製剤法 | |
FR2474312A1 (fr) | Nouvelles compositions anti-microbiennes pour le traitement topique de l'acne vulgaire | |
FR2490492A1 (fr) | Composition cosmetique pour le traitement local de la cellulite | |
FR2561914A1 (fr) | Nouvelle composition d'eau dentifrice et procede pour la preparer | |
FR2782923A1 (fr) | Procede de transformation d'une composition cosmetique en un film, film obtenu et kit | |
EP1187621A1 (fr) | Nouvelle association pharmaceutique a base d'erythromycine et d'un acide dicarboxylique ayant 7 a 13 atomes de carbone | |
EP0250300B1 (fr) | Utilisation des mélanges de sel de zinc et de la vitamine B6 pour enrayer les processus alopéciques et/ou séborrhéiques | |
FR2788436A1 (fr) | Composition d'un derive de phenothiazine | |
EP2819666A1 (fr) | Formulation gelifiante a base de gluconate de calcium | |
EP1265619A1 (fr) | Composition a base de sphingolipide et de beta-hydroxy-acide pour les soins de la peau | |
EP1965786A2 (fr) | Compositions comprenant au moins un compose retinoide et au moins un compose anti-irritant et leurs utilisations | |
FR2539991A1 (fr) | Onguent gras contenant notamment du butyro-propionate d'hydrocortisone, son procede de preparation et son application therapeutique | |
EP0200607B1 (fr) | Nouveaux sels de chlorhexidine tensioactifs et compositions les contenant | |
JP2017193503A (ja) | 消臭化粧料 | |
FR2694694A1 (fr) | Composition active pour le traitement du psoriasis, notamment le psoriasis du cuir chevelu. | |
EP0197876B1 (fr) | Composition thérapeutique utilisable en dermatologie contenant de l'imidazolidinylurée comme principe actif | |
EP1247521B1 (fr) | Utilisation d'un dérivé de biguanide et d'une pyrimidine pour la fabrication d'une composition topique pour le soin de la peau | |
FR2519552A1 (fr) | Procede pour stabiliser le lysozyme dans une composition liquide ou semi-liquide, et composition stabilisee a base de lysozyme | |
BE1015498A5 (fr) | Composition et utilisation de l'iode pur dissout dans l'huile essentielle de melaleuca alternifolia et/ou de melaleuca quinquinervia. | |
CA1221635A (fr) | Composition a activite pharmaceutique amelioree et utilisation de celle-ci pour des usages veterinaires | |
EP0288342A1 (fr) | Compositions cosmétiques et pharmaceutiques à application topique contenant un acide dicarboxylique de C 7 à C 13, un sel soluble de zinc et de la vitamine B6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000945978 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000945978 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000945978 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |